95 research outputs found
Targeting ERβ to fight melanoma: a new valid approach?
The impact of sex steroids and their cognate receptors in many human cancers has been almost neglected for many years.
Gender disparities in melanoma, with a female advantage in its incidence and outcome have been reported. However, the molecular aspects of these findings remain still pending, with few reports so far collected on the role of estrogen receptors (ERs), alpha (ERα) or beta (ERβ), or G-protein coupled estrogen receptor (GPER) in this cancer. ERs both mediate estrogen signaling through genomic or non-genomic mechanism, which might cooperate each other to regulate a range of responses in target tissues and human cancers. The subsequent discovery that an orphan GPCR (GPR30, then renamed GPER) is required for rapid estrogen signaling opened new perspectives in estrogen biology and hormone-dependent cancers [3]. ERβ can be detected in benign nevi, pre-malignant and malignant melanocytic lesions. As such, it might represent a hallmark of melanoma progression. A role for GPER has been also proposed in differentiation and growth inhibition of melanoma cells, as well as their susceptibility to immune clearance. GPER increased expression is correlated with reduced overall survival (OS) in melanoma patients
A Small Peptide Targeting the Ligand-Induced Androgen Receptor/Filamin a Interaction Inhibits the Invasive Phenotype of Prostate Cancer Cells
:Prostate cancer (PC) is one of the most widespread malignancies among males worldwide. The androgen receptor (AR) plays a major role in prostate cancer development and progression and is the main target of PC therapy. Nonetheless, its action is not yet fully elucidated. We report here that the AR associates with Filamin A (FlnA) promoting migration and invasiveness of various PC-derived cells after androgen challenging. Inhibition of the AR/FlnA complex assembly by a very low concentration of Rh-2025u, an AR-derived peptide specifically interfering with this association, impairs such phenotype in monolayer cells and in 3D models. This study, together with our recent data in cancer-associated fibroblasts (CAFs), indicates that targeting the AR/FlnA complex could improve the clinical management of invasive PC, as the limited number of new drugs reaching the market suggests that we must re-examine the way invasive PC is currently treated. In this context, the synthesis of new biologically active molecules, such as the Rh-2025u peptide, which has been shown to efficiently interfere in the complex assembly in CAFs and PC cells, should overcome the limits of current available therapies, mostly based on hormone hormone antagonists
Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells.
Triple-negative breast cancer is a heterogeneous disease that still lacks specific
therapeutic approaches. The identification of new biomarkers, predictive of the disease’s
aggressiveness and pharmacological response, is a challenge for a more tailored
approach in the clinical management of patients. Nerve growth factor, initially identified
as a key factor for neuronal survival and differentiation, turned out to be a multifaceted
molecule with pleiotropic effects in quite divergent cell types, including cancer cells.
Many solid tumors exhibit derangements of the nerve growth factor and its receptors,
including the tropomyosin receptor kinase A. This receptor is expressed in triple-negative
breast cancer, although its role in the pathogenesis and aggressiveness of this disease is
still under investigation. We now report that triple-negative breast cancer-derived MDAMB-
231 and MDA-MB-453 cells express appreciable levels of tropomyosin receptor
kinase A and release a biologically active nerve growth factor. Activation of tropomyosin
receptor kinase by nerve growth factor treatment positively affects the migration,
invasion, and proliferation of triple-negative breast cancer cells. An increase in the size
of triple-negative breast cancer cell spheroids is also detected. This latter effect might
occur through the nerve growth factor-induced release of matrix metalloproteinase 9,
which contributes to the reorganization of the extracellular matrix and cell invasiveness.
The tropomyosin receptor kinase A inhibitor GW441756 reverses all these responses.
Co-immunoprecipitation experiments in both cell lines show that nerve growth factor
triggers the assembly of the TrkA/b1-integrin/FAK/Src complex, thereby activating
several downstream effectors. GW441756 prevents the complex assembly induced by
nerve growth factor as well as the activation of its dependent signaling. Pharmacological
inhibition of the tyrosine kinases Src and FAK (focal adhesion kinase), together with the
silencing of b1-integrin, shows that the tyrosine kinases impinge on both proliferation
and motility, while b1-integrin is needed for motility induced by nerve growth factor in
triple-negative breast cancer cells. The present data support the key role of the nerve
growth factor/tropomyosin receptor kinase A pathway in triple-negative breast cancer
and offer new hints in the diagnostic and therapeutic management of patients
Communication between cells: exosomes as a delivery system in prostate cancer.
Despite the considerable efforts in screening and diagnostic protocols, prostate cancer still represents the second
leading cause of cancer-related death in men. Many patients with localized disease and low risk of recurrence have a
favourable outcome. In a substantial proportion of patients, however, the disease progresses and becomes aggressive.
The mechanisms that promote prostate cancer progression remain still debated. Many findings point to the role
of cross-communication between prostate tumor cells and their surrounding microenvironment during the disease
progression. Such a connection fosters survival, proliferation, angiogenesis, metastatic spreading and drug-resistance
of prostate cancer. Recent years have seen a profound interest in understanding the way by which prostate cancer
cells communicate with the surrounding cells in the microenvironment. In this regard, direct cell-to-cell contacts and
soluble factors have been identified. Increasing evidence indicates that PC cells communicate with the surrounding
cells through the release of extracellular vesicles, mainly the exosomes. By directly acting in stromal or prostate cancer
epithelial cells, exosomes represent a critical intercellular communication system. By querying the public database
(https:// pubmed. ncbi. nlm. nih. gov) for the past 10 years, we have found more than four hundred papers. Among
them, we have extrapolated the most relevant about the role of exosomes in prostate cancer malignancy and progression.
Emerging data concerning the use of these vesicles in diagnostic management and therapeutic guidance of
PC patients are also presented
Therapeutic potential of TRPM8 antagonists in prostate cancer.
Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer,
although its mechanism of action remains unclear. Here, we have characterized and investigated
the effects of TRPM8 modulators in prostate cancer aggressiveness disclosing the molecular
mechanism underlying their biological activity. Patch-clamp and calcium fluorometric assays were
used to characterize the synthesized compounds. Androgen-stimulated prostate cancer-derived
cells were challenged with the compounds and the DNA synthesis was investigated in a preliminary
screening. The most effective compounds were then employed to inhibit the pro-metastatic behavior
of in various PC-derived cells, at different degree of malignancy. The effect of the compounds
was then assayed in prostate cancer cell-derived 3D model and the molecular targets of selected
compounds were lastly identified using transcriptional and non-transcriptional reporter assays.
TRPM8 antagonists inhibit the androgen-dependent prostate cancer cell proliferation, migration
and invasiveness. They are highly effective in reverting the androgen-induced increase in prostate
cancer cell spheroid size. The compounds also revert the proliferation of castrate-resistant prostate
cancer cells, provided they express the androgen receptor. In contrast, no effects were recorded in
prostate cancer cells devoid of the receptor. Selected antagonists interfere in non-genomic androgen
action and abolish the androgen-induced androgen receptor/TRPM8 complex assembly as well as the
increase in intracellular calcium levels in prostate cancer cells. Our results shed light in the processes
controlling prostate cancer progression and make the transient receptor potential melastatin-8 as a
‘druggable’ target in the androgen receptor-expressing prostate cancers
The androgen receptor/filamin A complex as a target in prostate cancer microenvironment.
Prostate cancer represents the major cause of cancer-related death in men and patients frequently develop drug-resistance and metastatic disease. Most studies focus on hormone-resistance mechanisms related to androgen receptor mutations or to the acquired property of prostate cancer cells to over-activate signalling pathways. Tumour microenvironment plays a critical role in prostate cancer progression. However, the mechanism involving androgen/androgen receptor signaling in cancer associated fibroblasts and consequences for prostate cancer progression still remains elusive.
We now report that prostate cancer associated fibroblasts express a transcriptional-incompetent androgen receptor. Upon androgen challenging, the receptor co-localizes with the scaffold protein filamin A in the extra-nuclear compartment of fibroblasts, thus mediating their migration and invasiveness. Cancer-associated fibroblasts move towards epithelial prostate cancer cells in 2D and 3D cultures, thereby inducing an increase of the prostate cancer organoid size. Androgen enhances both these effects through androgen receptor/filamin A complex assembly in cancer-associated fibroblasts. An androgen receptor-derived stapled peptide, which disrupts the androgen receptor/filamin A complex assembly, abolishes the androgen-dependent migration and invasiveness of cancer associated fibroblasts. Notably, the peptide impairs the androgen-induced invasiveness of CAFs in 2D models and reduces the overall tumour area in androgen-treated 3D co-culture. The androgen receptor in association with β1 integrin and membrane type-matrix metalloproteinase 1 activates a protease cascade triggering extracellular matrix remodeling. The peptide also impairs the androgen activation of this cascade.
The present study offers a potential new marker, the androgen receptor/filamin A complex, and a new therapeutic approach targeting intracellular pathways activated by the androgen/androgen receptor axis in prostate cancer-associated fibroblasts. Such a strategy, alone or in combination with conventional therapies, may allow a more efficient treatment of prostate cancer
The Role of Curcumin in Prostate Cancer Cells and Derived Spheroids
A major challenge in the clinical management of prostate cancer (PC) is to inhibit tumor growth and prevent metastatic spreading. In recent years, considerable efforts have been made to discover new compounds useful for PC therapy, and promising advances in this field were reached. Drugs currently used in PC therapy frequently induce resistance and PC progresses toward metastatic castration-resistant forms (mCRPC), making it virtually incurable. Curcumin, a commercially avail- able nutritional supplement, represents an attractive therapeutic agent for mCRPC patients. In the present study, we compared the effects of chemotherapeutic drugs such as docetaxel, paclitaxel, and cisplatin, to curcumin, on two PC cell lines displaying a different metastatic potential: DU145 (moder- ate metastatic potential) and PC-3 (high metastatic potential). Our results revealed a dose-dependent reduction of DU145 and PC-3 cell viability upon treatment with curcumin similar to chemotherapeutic agents (paclitaxel, cisplatin, and docetaxel). Furthermore, we explored the EGFR-mediated signaling effects on ERK activation in DU145 and PC-3 cells. Our results showed that DU145 and PC-3 cells overexpress EGFR, and the treatment with chemotherapeutic agents or curcumin reduced EGFR expression levels and ERK activation. Finally, chemotherapeutic agents and curcumin reduced the size of DU145 and PC-3 spheroids and have the potential to induce apoptosis and also in Matrigel. In conclusion, despite different studies being carried out to identify the potential synergistic curcumin combinations with chemopreventive/therapeutic efficacy for inhibiting PC growth, the results show the ability of curcumin used alone, or in combinatorial approaches, to impair the size and the viability of PC-derived spheroids
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.
Abstract not availabl
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
Introduction: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. Methods: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. Results: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42% 60% of patients, and more often than sitagliptin or empagliflozin. Conclusion: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management
- …